These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 8281133)

  • 1. Adverse events temporally associated with immunizing agents--1991 report.
    Can Commun Dis Rep; 1993 Oct; 19(20):168-78. PubMed ID: 8281133
    [No Abstract]   [Full Text] [Related]  

  • 2. Adverse events temporally associated with immunizing agents: 1987 report.
    CMAJ; 1989 Nov; 141(9):933-7. PubMed ID: 2804852
    [No Abstract]   [Full Text] [Related]  

  • 3. Adverse events temporally associated with immunizing agents: 1989 report.
    CMAJ; 1991 Nov; 145(10):1269-75. PubMed ID: 1933709
    [No Abstract]   [Full Text] [Related]  

  • 4. Adverse events temporally associated with immunizing agents--1988 report.
    Duclos P; McCarthy R; Koch J; Carter A
    Can Dis Wkly Rep; 1990 Aug; 16(32):157-64. PubMed ID: 2208346
    [No Abstract]   [Full Text] [Related]  

  • 5. Adverse events temporally associated with immunizing agents: 1988 report.
    CMAJ; 1991 Feb; 144(3):325-9. PubMed ID: 1989712
    [No Abstract]   [Full Text] [Related]  

  • 6. Adverse events temporally associated with immunizing agents--1989 report.
    Duclos P; Koch J; Hardy M; Carter A; McCarthy R
    Can Dis Wkly Rep; 1991 Jul; 17(29):147-51, 155-7. PubMed ID: 1913934
    [No Abstract]   [Full Text] [Related]  

  • 7. Adverse events temporally associated with immunizing agents.
    Duclos P; Pless R; Koch J; Hardy M
    Can Fam Physician; 1993 Sep; 39():1907-13. PubMed ID: 8219839
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adverse events temporally associated with vaccines--1992 report.
    Bentsi-Enchill A; Hardy M; Koch J; Duclos P
    Can Commun Dis Rep; 1995 Jul; 21(13):117-28. PubMed ID: 7663460
    [No Abstract]   [Full Text] [Related]  

  • 9. [Prolonged convulsive disease states of the child. Etiological, therapeutic and prognostic aspects (apropos of 100 cases)].
    Pinsard N; Fieschi J; Rufo M; Saint-Jean M; Nezri M; Bernard R
    Pediatrie; 1974; 29(7):669-77. PubMed ID: 4456283
    [No Abstract]   [Full Text] [Related]  

  • 10. [Vaccines' adverse events: questions and answers brought by InfoVac].
    Cohen R; Siegrist CA
    Arch Pediatr; 2006 Jun; 13(6):650-2. PubMed ID: 16690277
    [No Abstract]   [Full Text] [Related]  

  • 11. [Immunization: adverse event reporting system].
    Weil-Olivier C; Jacquet A
    Arch Pediatr; 2006 Jun; 13(6):646-8. PubMed ID: 16697590
    [No Abstract]   [Full Text] [Related]  

  • 12. The monitoring of adverse events following immunization.
    Tatley M
    N Z Med J; 2002 Nov; 115(1165):U247; author reply U247. PubMed ID: 12552289
    [No Abstract]   [Full Text] [Related]  

  • 13. Adverse events temporally associated with meningococcal vaccines.
    Yergeau A; Alain L; Pless R; Robert Y
    CMAJ; 1996 Feb; 154(4):503-7. PubMed ID: 8630839
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adverse events after inactivated influenza vaccination among children less than 2 years of age: analysis of reports from the vaccine adverse event reporting system, 1990-2003.
    McMahon AW; Iskander J; Haber P; Chang S; Woo EJ; Braun MM; Ball R
    Pediatrics; 2005 Feb; 115(2):453-60. PubMed ID: 15687455
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A population-based, postlicensure evaluation of the safety of a combination diphtheria, tetanus, acellular pertussis, hepatitis B, and inactivated poliovirus vaccine in a large managed care organization.
    Zangwill KM; Eriksen E; Lee M; Lee J; Marcy SM; Friedland LR; Weston W; Howe B; Ward JI
    Pediatrics; 2008 Dec; 122(6):e1179-85. PubMed ID: 19047220
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Field evaluation of vaccine safety.
    Tozzi AE
    Vaccine; 2004 May; 22(15-16):2091-5. PubMed ID: 15121330
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oculo-respiratory syndrome following influenza vaccination: review of post-marketing surveillance through four influenza seasons in Canada.
    Can Commun Dis Rep; 2005 Nov; 31(21):217-25. PubMed ID: 16669126
    [No Abstract]   [Full Text] [Related]  

  • 18. Safety of Typhim Vi vaccine in a postmarketing observational study.
    Marcus LC; Froeschle JE; Hill DR; Wolfe MS; Maus D; Connor B; Acosta AM; Rensimer ER; Roberts A; Dardick K
    J Travel Med; 2007; 14(6):386-91. PubMed ID: 17995534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Postlicensure epidemiology of childhood vaccination: the Danish experience.
    Hviid A
    Expert Rev Vaccines; 2006 Oct; 5(5):641-9. PubMed ID: 17181438
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccine safety perceptions and experience with adverse events following immunization in Uzbekistan.
    Fowler GL; Weintraub E; Kennedy A; Luman ET; Shui I; Khromava A; Kohl K; Gust DA
    Public Health; 2008 Apr; 122(4):412-6. PubMed ID: 17961615
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.